| Name | Title | Contact Details |
|---|---|---|
Ryan Johnsen |
Chief Technology Officer | Profile |
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients` lives and addressing the liver community`s most pressing needs. Our corporate headquarters is located in New York, and we have additional offices in San Diego, London and Perugia.
We help you connect patients and researchers to ensure data reliability, with proven solutions that simplify every step of the patient journey. Our deep therapeutic area expertise, agile technology and service scale enable us to minimize risk, innovate, and support your important work. We seek speed, efficiency and reduced variability to help you extend the reach of drug development, expand patient opportunities and improve data quality helping you bring life-changing therapies to our families and communities around the world.
Concordia Pharmaceuticals is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Diapharma Group Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Allied Digestive Health is an integrated network of gastroenterology Care Centers. Our multi-specialty group is a dedicated, compassionate team...